Sygnature Discovery has added in-house high-throughput screening (HTS) to its range of drug discovery services. This is backed up by its new Leadfinder compound library.
AstraZeneca and FibroGen’s pooled cardiovascular (CV) safety analyses showed that roxadustat, an oral first-in-class hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), did not increase the risk of MACE, MACE+ and all-cause mortality in non dialysis-dependent (NDD) patients compared to placebo and dialysis-dependent (DD) patients compared to epoetin alfa, a current medicine used to treat anaemia.
Vaccibody with first neoantigen cancer vaccine to show induction of strong cancer-specific immune responses
Vaccibody AS, a clinical-stage biopharmaceutical company focused on cancer vaccines, announced in a press release on November 5, 2019 the positive initial data from the ongoing VB N-01 (DIRECT-01) phase I/IIa clinical trial of the VB10.NEO neoantigen cancer vaccine.
Arix Bioscience said Wednesday that its portfolio company Artios Pharma Ltd, has entered in-licensing agreement of a small-molecule ATR inhibitor programme from The University of Texas MD Anderson Cancer Center and ShangPharma.
Ubiquigent and LEO Pharma A/S have entered into an option agreement granting LEO Pharma access to two novel compounds, which comes after an earlier agreement between the parties entered into as part of LEO Pharma Open Innovation, without disclosing financial terms.
NOTTINGHAM, England–(BUSINESS WIRE)–Tufts Center for the Study of Drug Development (CSDD) today published a white paper sharing study results that
First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple Myeloma
Cellectis has had first patient dosed with off-the-Shelf UCARTCS1 product candidate for relapsed/refractory multiple myeloma. Read the full article
European Commission has approved a third indication for Dupixent® (dupilumab) for the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. It is also approved for moderate-to-severe atopic dermatitis and severe asthma.
DURHAM, N.C.–(BUSINESS WIRE)–Nuventra Pharma Sciences is pleased to announce the addition of Iftekhar Mahmood, Ph.D., to its growing team of
Company Making Progress on Strategic Priorities to Deliver Long-Term Growth, with sales increased 4.1 percent to $136.9 billion, up 5.8